Browse by Audience
Skip to content
Papers of the Week
Lasmiditan abortive therapy for episodic migraine in Phase II/III randomized clinical trials: A meta-analysis.
Abstract
Although migraine is common, there are very few treatment options. Recently, lasmiditan, a specific 5-HT agonist, has gained approval as abortive therapy for migraine. This meta-analysis and trial sequential analysis (TSA) was performed to analyze efficacy and tolerability of lasmiditan therapy for episodic migraine.